OyaGen: Tonix Pharma inks pact with OyaGen to develop antiviral SARSCoV2 inhibitor, TNX3500 to treat Covid19
Tonix Pharmaceuticals, a clinical─stage biopharmaceutical company, and OyaGen, a pre─clinical biotechnology research company, announced an exclusive worldwide licensing agreement for an antiviral inhibitor of
Read full article »
OyaGen focuses on the discovery, development and commercialization of pharmaceutical therapies to exploit RNA editing and DNA editing enzymes.
Read more